Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 3m Syndrome 3 C3280146
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 3M Syndrome 3 for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
3m Syndrome 3 C3280146
A genetic condition causing intrauterine growth restriction and postnatal short stature with distinctive facial features. Treatment focuses on growth monitoring and supportive measures.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
3m Syndrome 3 C3280146
0-0
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
3m Syndrome 3 C3280146
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
3m Syndrome 3 C3280146
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
3m Syndrome 3 C3280146
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3m Syndrome 3 C3280146
musculoskeletal
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3m Syndrome 3 C3280146
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 3m-syndrome-3-C3280146 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3m Syndrome 3 C3280146 | Discriminating power |
|---|---|---|---|
| Heart involvement | Cardiomyopathy or heart-muscle weakness may occur. | Heart disease is not a described core feature. | High |
| Growth pattern | Growth effects may occur but are not the defining feature. | Intrauterine growth restriction and postnatal short stature are characteristic. | High |
| Infections and muscle weakness | Recurrent infections and muscle weakness are described. | These are not established defining features. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant or child with cardiomyopathy
Fits the described mitochondrial, male-predominant pattern.
Moderate
Unexplained muscle weakness with recurrent infections
Supports consideration of Barth syndrome alongside specialist testing.
Moderate
Metabolic evaluation suggests organic aciduria
May direct testing, but an abnormal result is not itself a diagnosis.
Low
Choose 3m Syndrome 3 C3280146 when
Prenatal growth restriction with postnatal short stature
Matches the supplied growth-disorder description.
Moderate
Distinctive facial features with proportionate growth concern
Supports genetics referral rather than assuming a metabolic disease.
Moderate
No cardiomyopathy, infection pattern, or metabolic clue
Makes 3M syndrome relatively more plausible, but does not confirm it.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3m Syndrome 3 C3280146 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show elevated 3-methylglutaconic acid; cutoff not established here. | No characteristic organic-acid abnormality is established. | Abnormality supports specialist review but does not alone diagnose Barth syndrome. |
| Cardiac assessment | May reveal cardiomyopathy or reduced heart function. | No specific cardiac abnormality is described. | Findings require cardiology interpretation and do not exclude either condition. |
| Genetic testing | May identify a Barth syndrome-associated variant when clinically indicated. | May identify a 3M syndrome 3-associated variant when clinically indicated. | Diagnosis depends on accredited testing and clinical correlation. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Potentially severe chronic course; exact survival cannot be stated from these data.
- Factors
- Heart involvement, infections, muscle weakness, and access to supportive care.
3m Syndrome 3 C3280146
- Outcome
- Generally described as moderate, centered on persistent short stature.
- Factors
- Growth pattern, associated features, and supportive management.
Time frame: Both are chronic; left often presents from birth to early childhood, right from prenatal life.
Prognosis is individualized and not established by this comparison alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac complications | Heart-muscle weakness may cause serious illness. Not described as a typical complication. Urgent cardiac care is needed for concerning symptoms. |
| Infection risk | Recurrent infections are described. No established increased infection risk is supplied. Prevention strategies should be individualized. |
| Growth and skeletal impact | Not the primary described complication. Short stature and growth monitoring needs are central. Endocrine or orthopedic issues should not be assumed without evaluation. |
Patient education highlights
- HighDifferent conditions
These disorders affect different systems and should not be treated as interchangeable.
- HighWarning symptoms
Breathing difficulty, poor feeding, fainting, or severe infection needs urgent care.
- MediumFollow-up
Cardiac, infection, growth, and genetics plans depend on the confirmed diagnosis.